Several small retrospective cohort studies have reported the efficacy of ICI monotherapy in NSCLC patients with other diver oncogenic alterations, with response rates ranging from 0% in NSCLC patients with ALK fusion to 24% in NSCLC patients with BRAF mutation (40, 63, 64). Here, BRAF is linked to non-small cell lung carcinoma.